ROTH Stock Overview
PharmaRoth Labs, Inc. operates as a nutraceutical company worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
PharmaRoth Labs, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.0001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.94% |
5 Year Change | -99.94% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
ROTH | US Personal Products | US Market | |
---|---|---|---|
7D | 0% | -1.8% | 1.3% |
1Y | n/a | -27.1% | 29.8% |
Return vs Industry: Insufficient data to determine how ROTH performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how ROTH performed against the US Market.
Price Volatility
ROTH volatility | |
---|---|
ROTH Average Weekly Movement | n/a |
Personal Products Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ROTH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ROTH's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Luis Manuel Lopez | https://www.feroindustries.com |
PharmaRoth Labs, Inc. operates as a nutraceutical company worldwide. It focuses on producing, marketing, and distributing Sucanon, an herbal-based nutraceutical treatment for type-2 diabetes. The company was formerly known as Fero Industries Inc. and changed its name to PharmaRoth Labs, Inc. in March 2013.
PharmaRoth Labs, Inc. Fundamentals Summary
ROTH fundamental statistics | |
---|---|
Market cap | US$390.00 |
Earnings (TTM) | -US$557.63k |
Revenue (TTM) | US$200.15k |
0.0x
P/S Ratio0.0x
P/E RatioIs ROTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ROTH income statement (TTM) | |
---|---|
Revenue | US$200.15k |
Cost of Revenue | US$119.67k |
Gross Profit | US$80.48k |
Other Expenses | US$638.10k |
Earnings | -US$557.63k |
Last Reported Earnings
Mar 31, 2011
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ROTH perform over the long term?
See historical performance and comparison